Scan to download
BTC $60,186.17 +0.88%
ETH $1,609.71 +2.27%
BNB $559.05 +1.41%
XRP $1.05 +0.88%
SOL $75.00 +5.05%
TRX $0.3209 -0.29%
DOGE $0.0732 +0.13%
ADA $0.1457 +1.28%
BCH $200.32 +4.89%
LINK $7.37 +1.40%
HYPE $66.76 +8.50%
AAVE $91.43 +0.67%
SUI $0.7009 +2.78%
XLM $0.1744 +0.76%
ZEC $408.13 +8.15%
BTC $60,186.17 +0.88%
ETH $1,609.71 +2.27%
BNB $559.05 +1.41%
XRP $1.05 +0.88%
SOL $75.00 +5.05%
TRX $0.3209 -0.29%
DOGE $0.0732 +0.13%
ADA $0.1457 +1.28%
BCH $200.32 +4.89%
LINK $7.37 +1.40%
HYPE $66.76 +8.50%
AAVE $91.43 +0.67%
SUI $0.7009 +2.78%
XLM $0.1744 +0.76%
ZEC $408.13 +8.15%

Chainalysis: Gray market peptide suppliers are rapidly shifting to Bitcoin and stablecoins, with a year-on-year surge of 159% in crypto inflows in Q1

2026-06-05 08:24:45
Collection

According to The Block, blockchain analytics company Chainalysis has released a latest report indicating that as the gray market peptide industry scales surpasses an annualized $100 million, leading suppliers are accelerating the adoption of Bitcoin and stablecoins as primary settlement tools.

In Q1 2026, cryptocurrency inflows into the industry reached $32 million, a month-on-month surge of 159%. Due to traditional banks and credit card payment channels generally imposing bans on prescription-grade compounds and unregulated substances, a large number of Chinese chemical manufacturers are turning to cryptocurrency to complete transactions, with high-value orders particularly favoring stablecoins to avoid price volatility risks.

app_icon
ChainCatcher Building the Web3 world with innovations.